Nektar Therapeutics (NKTR) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and thank you for standing by. Welcome to the Nectar Therapeutics second quarter 2026 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Vivian Wu from Nectar Investor Relations to kick things off. Please go ahead. Thank you, Crystal, and good afternoon, everyone. Thank you for joining us today. On today's call, you will hear from Howard Robin, our President and Chief Executive Officer, Dr. Jonathan Zalevsky, our Chief Research and Development Officer, and Linda Rubinstein, our Chief Financial Officer. Dr. Mary Tagliaferri, our Chief Medical Officer, will also be available during the Q&A. Before we begin, I would like to remind you that we will be making forward-looking statements regarding our business, including statements related to therapeutic and commercial potential and development plans for Raspeg-Aldis-Lukin, the timing and expectations for clinical trials, clinical data presentations, and regulatory submissions. Regulatory interactions are expected cash runway and other statements regarding the future of our business. Because forward-looking statements relate to the future, There are subject uncertainties and risks that are difficult to predict, and many of which are outside of our control. For a discussion of these risks and uncertainties, please refer to our filings with SEC, including our most recent Form 10-K and subsequent filings. We undertake no obligation to update these forward linking statements, except as required by law. Live webcasts and replay of this call will be available on the impact relations section of our ...